Varun lobo (Talk | contribs) |
Varun lobo (Talk | contribs) |
||
Line 192: | Line 192: | ||
<h3>Project description</h3> | <h3>Project description</h3> | ||
<p> | <p> | ||
− | We are planning to use dCas9 and asRNA to silence the production of toxins A and B in <i>C. difficile</i> which is known for causing hospital-acquired diarrhoea in the Western world. We want to prove a concept of asRNA and/or dCas9 as an alternative to antibiotic treatment against <i>C.difficile</i>. As a result, we will neutralise the negative impacts of bacteria on human health rather than completely killing it. | + | We are planning to use dCas9 and asRNA to silence the production of toxins A and B in <i>C. difficile</i> which is known for causing hospital-acquired diarrhoea in the Western world. We want to prove a concept of asRNA and/or dCas9 as an alternative to antibiotic treatment against <i>C. difficile</i>. As a result, we will neutralise the negative impacts of bacteria on human health rather than completely killing it. |
We will create and test a promoter library in both <i>E. coli</i> and <i>C. difficile</i>, express anti-sense RNAs in <i>C. difficile</i>, express dCas9/sgRNA in <i>E. coli</i> and <i>C. difficile</i>. dCas9 is planned to be used to repress the reporter gene <i>gusA</i>, by dCas9 binding to the toxin promoters placed upstream of <i>gusA</i>, in <i>E. coli</i> and <i>C. difficile</i>. If this repression is successful the system will be used to repress the <i>C. difficile</i> toxin genes. | We will create and test a promoter library in both <i>E. coli</i> and <i>C. difficile</i>, express anti-sense RNAs in <i>C. difficile</i>, express dCas9/sgRNA in <i>E. coli</i> and <i>C. difficile</i>. dCas9 is planned to be used to repress the reporter gene <i>gusA</i>, by dCas9 binding to the toxin promoters placed upstream of <i>gusA</i>, in <i>E. coli</i> and <i>C. difficile</i>. If this repression is successful the system will be used to repress the <i>C. difficile</i> toxin genes. | ||
</p> | </p> | ||
Line 201: | Line 201: | ||
<div class="ui bulleted list"> | <div class="ui bulleted list"> | ||
<div class="item">E.coli DH5 alpha, E. coli sexpress (NEB express + R702)</div> | <div class="item">E.coli DH5 alpha, E. coli sexpress (NEB express + R702)</div> | ||
− | <div class="item"><i>C.difficile</i> SBRC 078 (clinical isolate), <i>C.difficile</i> bacteriophage phiSBRC</div> | + | <div class="item"><i>C. difficile</i> SBRC 078 (clinical isolate), <i>C. difficile</i> bacteriophage phiSBRC</div> |
</div> | </div> | ||
Line 216: | Line 216: | ||
<div class="ui bulleted list"> | <div class="ui bulleted list"> | ||
<div class="item">E.coli DH5 alpha, E. coli sexpress (NEB express + R702)</div> | <div class="item">E.coli DH5 alpha, E. coli sexpress (NEB express + R702)</div> | ||
− | <div class="item"><i>C.difficile</i> SBRC 078 (clinical isolate)</div> | + | <div class="item"><i>C. difficile</i> SBRC 078 (clinical isolate)</div> |
</div> | </div> | ||
Line 228: | Line 228: | ||
The SBRC have risk assessments and waste disposal management that will ensure that chassis are not released into the environment as they possess antibiotic resistance that could be spread to other bacteria. Except that, <i>E. coli</i> strains used do not possess pathogenic properties and therefore pose minimal to no risk to human health. | The SBRC have risk assessments and waste disposal management that will ensure that chassis are not released into the environment as they possess antibiotic resistance that could be spread to other bacteria. Except that, <i>E. coli</i> strains used do not possess pathogenic properties and therefore pose minimal to no risk to human health. | ||
<br><br> | <br><br> | ||
− | <i>C.difficile</i> could pose a risk to human health in immunocompromised patients or patients receiving antibiotic therapy. However, they would need to ingest spores, which can be removed with hand washing. Colleagues or team members are not authorised to enter the lab whilst on antibiotic therapy. Providing correct PPE is worn and hand washing procedures are followed, <i>C.difficile</i> will not pose a risk to the lab-based team members. Release of <i>C.difficile</i> into environment could cause a hazard due to production of spores that can survive in the environment for a long time. The lab follows specific disposal rules for <i>C.difficile</i> | + | <i>C. difficile</i> could pose a risk to human health in immunocompromised patients or patients receiving antibiotic therapy. However, they would need to ingest spores, which can be removed with hand washing. Colleagues or team members are not authorised to enter the lab whilst on antibiotic therapy. Providing correct PPE is worn and hand washing procedures are followed, <i>C. difficile</i> will not pose a risk to the lab-based team members. Release of <i>C. difficile</i> into environment could cause a hazard due to production of spores that can survive in the environment for a long time. The lab follows specific disposal rules for <i>C. difficile</i> in accordance with standard operating procedures and risk assessments. |
</p> | </p> | ||
Line 235: | Line 235: | ||
E.coli sexpress (NEB express +R702) is a new strain created at SBRC Nottingham and the research paper on it has not been published yet. | E.coli sexpress (NEB express +R702) is a new strain created at SBRC Nottingham and the research paper on it has not been published yet. | ||
− | <i>C.difficile</i>SBRC 078 is a clinical isolate of <i>C.difficile</i> belonging to PCR ribotype 078. | + | <i>C. difficile</i>SBRC 078 is a clinical isolate of <i>C. difficile</i> belonging to PCR ribotype 078. |
</div> | </div> | ||
Line 244: | Line 244: | ||
<h3>Experiments undertaken with organisms and parts</h3> | <h3>Experiments undertaken with organisms and parts</h3> | ||
<p> | <p> | ||
− | All parts will be used to create and test a promoter library in both <i>E. coli</i> and <i>C.difficile</i>, express asRNAs in <i>C.difficile</i> express dCas9/sgRNA in <i>E. coli</i> and <i>C.difficile</i>. The asRNAs will be used to repress the expression of toxin A and B in <i>C.difficile</i>. dCas9 will be used to repress the reporter gene <i>gusA</i> (Cas9 binding to the toxin promoters placed upstream of <i>gusA</i>) in <i>E. coli</i> and <i>C.difficile</i>.If this repression is successful the system will be used to repress the <i>C.difficile</i> toxin genes. | + | All parts will be used to create and test a promoter library in both <i>E. coli</i> and <i>C. difficile</i>, express asRNAs in <i>C. difficile</i> express dCas9/sgRNA in <i>E. coli</i> and <i>C. difficile</i>. The asRNAs will be used to repress the expression of toxin A and B in <i>C. difficile</i>. dCas9 will be used to repress the reporter gene <i>gusA</i> (Cas9 binding to the toxin promoters placed upstream of <i>gusA</i>) in <i>E. coli</i> and <i>C. difficile</i>.If this repression is successful the system will be used to repress the <i>C. difficile</i> toxin genes. |
<br><br> | <br><br> | ||
− | If toxin | + | If toxin suppression in <i>E. coli</i> is successful, we plan to use <i>E. coli</i> sexpress (NEB express + R702) to conjugate <i>E. coli</i> containing asRNA or dCas9 vector into <i>C. difficile</i> SBRC 078 to test toxin suppression in the host organism. Given enough time, we plan to insert asRNA/dCas9 system into <i>C. difficile</i> bacteriophage phiSBRC as an ultimate test of our project efficacy. |
</p> | </p> | ||
Line 262: | Line 262: | ||
<div class="ui divider"></div> | <div class="ui divider"></div> | ||
<h3>How real people would use our product</h3> | <h3>How real people would use our product</h3> | ||
− | <p> | + | <p>Our product would be used in the human body, or in food (Examples: anti-cancer bacteria, bread made with engineered yeast, engineered rice plants)</p> |
<div class="ui red segment"> | <div class="ui red segment"> | ||
<h3 class="ui red small header">Risks associated with real use</h3> | <h3 class="ui red small header">Risks associated with real use</h3> | ||
<p> | <p> | ||
− | Our project is basically focused on proving the concept that one can use bacteriophage therapy against <i>C.difficile</i>. We wanted to explore alternative treatment options due to the increasing problem of antibiotic resistance. Of course, we do not claim in any way that our final product will be straight away ready for therapeutic use. In the best scenario, it would need to be tested <i>in vivo</i> in pre-clinical studies and in clinical trials to assess their safety and test for any side effects. This would be done with ethical approval. Pharmacokinetic studies and biochemical experiments would be carried out to determine optimum conditions for use. | + | Our project is basically focused on proving the concept that one can use bacteriophage therapy against <i>C. difficile</i>. We wanted to explore alternative treatment options due to the increasing problem of antibiotic resistance. Of course, we do not claim in any way that our final product will be straight away ready for therapeutic use. In the best scenario, it would need to be tested <i>in vivo</i> in pre-clinical studies and in clinical trials to assess their safety and test for any side effects. This would be done with ethical approval. Pharmacokinetic studies and biochemical experiments would be carried out to determine optimum conditions for use. |
<br><br> | <br><br> | ||
− | Our project is focused on using phage. Even though it is specific to <i>C.difficile</i>, its specificity may vary depending on different conditions. More research would be needed to investigate possible non-specific infection. | + | Our project is focused on using phage. Even though it is specific to <i>C. difficile</i>, its specificity may vary depending on different conditions. More research would be needed to investigate possible non-specific infection. |
</p> | </p> | ||
</div> | </div> | ||
Line 275: | Line 275: | ||
<h3>How experts have overseen our project to manage identified risk</h3> | <h3>How experts have overseen our project to manage identified risk</h3> | ||
<p> | <p> | ||
− | Michelle Kelly, one of the safety officers at the lab our team has been working in, carried out a full laboratory safety induction and introduced the risk assessments and standard operating procedures that are adhered to when working in a Category 2 laboratory. She has also set up training records for each team member which requires signing off by advisors when each lab skill has been efficiently performed. She has been working on <i>C.difficile</i> for more than 5 years and possesses deep knowledge into proper project design that ensures safety of the researcher. | + | Michelle Kelly, one of the safety officers at the lab our team has been working in, carried out a full laboratory safety induction and introduced the risk assessments and standard operating procedures that are adhered to when working in a Category 2 laboratory. She has also set up training records for each team member which requires signing off by advisors when each lab skill has been efficiently performed. She has been working on <i>C. difficile</i> for more than 5 years and possesses deep knowledge into proper project design that ensures safety of the researcher. |
<br><br> | <br><br> | ||
− | Nigel Minton (PI) has worked on <i>C.difficile</i> and Clostridia for over 20 years and has overseen the project development. Four other advisors who will also oversee the work that is completed, all of whom have worked on Clostridia for at least 3 years. These researchers will be responsible for ensuring SOPs and RAs are followed on a day to day basis. All parts of our project fall under university biosafety regulations as was checked by PI and safety officer. | + | Nigel Minton (PI) has worked on <i>C. difficile</i> and Clostridia for over 20 years and has overseen the project development. Four other advisors who will also oversee the work that is completed, all of whom have worked on Clostridia for at least 3 years. These researchers will be responsible for ensuring SOPs and RAs are followed on a day to day basis. All parts of our project fall under university biosafety regulations as was checked by PI and safety officer. |
</p><div class="ui divider"></div> | </p><div class="ui divider"></div> | ||
<h3>Rules and guidance cover that helped manage identified risks</h3> | <h3>Rules and guidance cover that helped manage identified risks</h3> | ||
Line 325: | Line 325: | ||
<br><br> | <br><br> | ||
All wet lab members were trained to work in group risk 2 laboratory and using the facilities. All regulations regarding waste disposal, equipment use and handling of dangerous chemicals were introduced by the safety officer. At least one supervisor was always present in the lab to ensure that the safety protocols are followed thoroughly. | All wet lab members were trained to work in group risk 2 laboratory and using the facilities. All regulations regarding waste disposal, equipment use and handling of dangerous chemicals were introduced by the safety officer. At least one supervisor was always present in the lab to ensure that the safety protocols are followed thoroughly. | ||
− | In addition to standard procedures for working within a category 2 laboratory due to the nature of <i>C.difficile</i> no member of the team can enter the lab when they are taking antibiotics. | + | In addition to standard procedures for working within a category 2 laboratory due to the nature of <i>C. difficile</i> no member of the team can enter the lab when they are taking antibiotics. |
</p> | </p> | ||
</div> | </div> |
Revision as of 09:26, 17 October 2018